Next Article in Journal
Influenza Virus and Vaccination
Next Article in Special Issue
Encystment Induces Down-Regulation of an Acetyltransferase-Like Gene in Acanthamoeba castellanii
Previous Article in Journal
Intelligent Mechanisms of Macrophage Apoptosis Subversion by Mycobacterium
Previous Article in Special Issue
Description of Virulent Factors and Horizontal Gene Transfers of Keratitis-Associated Amoeba Acanthamoeba Triangularis by Genome Analysis
Article

Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops against Acanthamoeba castellanii Neff: In Vitro Assay Based on Mixture Design

1
Instituto Universitario De Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, La Laguna, Tenerife, 38203 Islas Canarias, Spain
2
Departamento de Obstetricia, Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad De La Laguna, La Laguna, Tenerife, 38203 Islas Canarias, Spain
3
Servicio de Oftalmología, Hospital Universitario Nuestra Señora de la Candelaria, Canarias, Tenerife, 38010 Islas Canarias,, Spain
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Pathogens 2020, 9(3), 219; https://doi.org/10.3390/pathogens9030219
Received: 27 January 2020 / Revised: 12 March 2020 / Accepted: 13 March 2020 / Published: 17 March 2020
The establishment of an effective therapeutic agent against Acanthamoeba keratitis (AK), remains until present, an issue to be solved due to the existence of a cyst stage in the life cycle of Acanthamoeba. Moreover, the effectiveness of the current standard therapeutic agents varies depending on the tested Acanthamoeba strains and its resistance pattern. In the present study, two 10-point augmented simplex-centroid designs were used to formulate a three-component mixture system using water, atorvastatin, and Diclofenaco-lepori or Optiben. The amoebicidal effects and in vitro-induced toxicity in a eukaryotic cell line were determined for all experiments. The optimal mixture to inhibit the parasite without inducing toxicity was established in the first plan as 30% Optiben, 63.5% atorvastatin, and 3.1% water. As for the second experimental design, the optimal mixture to inhibit Acanthamoeba with lower toxicity effect was composed of 17.6% Diclofenaco-lepori and 82.4% atorvastatin. View Full-Text
Keywords: Acanthamoeba keratitis; chemotherapy; atorvastatin; Diclofenaco-lepori; mixture design Acanthamoeba keratitis; chemotherapy; atorvastatin; Diclofenaco-lepori; mixture design
Show Figures

Figure 1

MDPI and ACS Style

Sifaoui, I.; Capote Yanes, E.; Reyes-Batlle, M.; Rodríguez-Expósito, R.L.; Piñero, J.E.; Lorenzo-Morales, J. Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops against Acanthamoeba castellanii Neff: In Vitro Assay Based on Mixture Design. Pathogens 2020, 9, 219. https://doi.org/10.3390/pathogens9030219

AMA Style

Sifaoui I, Capote Yanes E, Reyes-Batlle M, Rodríguez-Expósito RL, Piñero JE, Lorenzo-Morales J. Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops against Acanthamoeba castellanii Neff: In Vitro Assay Based on Mixture Design. Pathogens. 2020; 9(3):219. https://doi.org/10.3390/pathogens9030219

Chicago/Turabian Style

Sifaoui, Ines, Eulalia Capote Yanes, María Reyes-Batlle, Rubén L. Rodríguez-Expósito, José E. Piñero, and Jacob Lorenzo-Morales. 2020. "Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops against Acanthamoeba castellanii Neff: In Vitro Assay Based on Mixture Design" Pathogens 9, no. 3: 219. https://doi.org/10.3390/pathogens9030219

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop